{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:19Z","timestamp":1787003599249,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Zhejiang Province","award":["LQ19H160042"],"award-info":[{"award-number":["LQ19H160042"]}]},{"name":"the Natural Science Foundation of Zhejiang Province","award":["LQ20H160028"],"award-info":[{"award-number":["LQ20H160028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adjuvant oxaliplatin plus S-1 (SOX) chemotherapy\u00a0for\u00a0gastric cancer (GC) after D2 gastrectomy has been proven effective. There has yet to be a study that evaluates adjuvant nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus S-1. In this single-center, retrospective study, GC patients after D2 gastrectomy received either nab-paclitaxel plus S-1 (AS group) or SOX group were recruited between January 2018 and December 2020 in The First Affiliated Hospital of Zhejiang University. Intravenous nab-paclitaxel 120\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    or 260\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    and oxaliplatin 130\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    were administered as eight 3\u00a0week cycle, especially in the AS and SOX group. Patients received S-1 twice daily with a dose of 40\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    in the two groups on days 1\u201314 of each cycle. The end points were disease-free survival (DFS) rate at 3\u00a0years and adverse events (AEs). There were 56 eligible patients, 28 in the AS group and 35 in the SOX group. The 3\u00a0year DFS rate was 78.0% in AS group versus 70.7% in SOX group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.46). Subgroup analysis showed that the patients with signet-ring positive in the AS group had a prolonged DFS compared with the SOX group (40.0 vs. 13.8\u00a0m,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). The diffuse-type GC or low differentiation in the AS group was associated with numerically prolonged DFS compared with the SOX group, but the association was not statistically significant (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.27 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.15 especially). Leukopenia (14.3%) were the most prevalent AEs in the AS group, while thrombocytopenia (28.5%) in the SOX group. Neutropenia (7.1% in AS group) and thrombocytopenia (22.8% in SOX group) were the most common grade 3 or 4 AEs. In this study analyzing past data, a tendency towards a greater 3\u00a0year DFS was observed when using AS regimen in signet-ring positive patients. AS group had fewer thrombocytopenia compared to SOX group. More studies should be conducted with larger sample sizes.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-65724-8","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:04:09Z","timestamp":1719896649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"65724_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"65724_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. (Engl) 135, 584\u2013590 (2022).","journal-title":"Chin. Med. J. (Engl)"},{"key":"65724_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","volume":"240","author":"M D'Angelica","year":"2004","unstructured":"D\u2019Angelica, M. et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann. Surg. 240, 808\u2013816 (2004).","journal-title":"Ann. Surg."},{"key":"65724_CR4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810\u20131820 (2007).","journal-title":"N. Engl. J. Med."},{"key":"65724_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315\u2013321 (2012).","journal-title":"Lancet"},{"key":"65724_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-021-01224-2","volume":"25","author":"Y Kakeji","year":"2022","unstructured":"Kakeji, Y. et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer 25, 188\u2013196 (2022).","journal-title":"Gastric Cancer"},{"key":"65724_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22, 1081\u20131092 (2021).","journal-title":"Lancet Oncol"},{"key":"65724_CR8","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial. JAMA 330, 2064\u20132074 (2023).","journal-title":"JAMA"},{"key":"65724_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ijc.34296","volume":"152","author":"T Liu","year":"2023","unstructured":"Liu, T. et al. First-line nivolumab plus chemotherapy vs. chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int. J. Cancer 152, 749\u2013760 (2023).","journal-title":"Int. J. Cancer"},{"key":"65724_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"65724_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212 (2023).","journal-title":"Lancet Oncol."},{"key":"65724_CR12","doi-asserted-by":"crossref","unstructured":"Terashima, M., Kang, Y.K., Kim, Y.-W., Boku, N., Chung, H.-C.-C., Chen, J.-S., Ji, J., Yeh, T.-S., Chen, L.-T., Ryu, M.-H., Kim, J.-G., Omori, T., Rha, S.-Y., Kim, T.-Y., Ryu, K.-W., Sakuramoto, S., Nishida, Y., Fukushima, N., Yamada, T. Sasako, M. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G\/GEJ) cancer. In: 2023 ASCO Annual Meeting I: gastrointestinal cancer\u2014gastroesophageal, pancreatic, and hepatobiliary, (abstr 4000), (2023)","DOI":"10.1200\/JCO.2023.41.16_suppl.4000"},{"key":"65724_CR13","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"65724_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/imt-2020-0179","volume":"13","author":"FG Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis. Immunotherapy 13, 257\u2013270 (2021).","journal-title":"Immunotherapy"},{"key":"65724_CR15","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00262-023-03366-x","volume":"72","author":"A Rizzo","year":"2023","unstructured":"Rizzo, A. et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: The MOUSEION-05 study. Cancer Immunol. Immunother. 72, 1381\u20131394 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"65724_CR16","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial. Lancet 393, 1948\u20131957 (2019).","journal-title":"Lancet"},{"key":"65724_CR17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran, S. E. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 17, 1697\u20131708 (2016).","journal-title":"Lancet Oncol."},{"key":"65724_CR18","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang, Y. K. et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J. Clin. Oncol. 39, 2903\u20132913 (2021).","journal-title":"J. Clin. Oncol."},{"key":"65724_CR19","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.3390\/cancers15133342","volume":"15","author":"R Giampieri","year":"2023","unstructured":"Giampieri, R. et al. Impact of signet-ring cell histology in the management of patients with non-metastatic gastric cancer: Results from a retrospective multicenter analysis comparing FLOT perioperative chemotherapy vs. surgery followed by adjuvant chemotherapy. Cancers (Basel) 15, 3342 (2023).","journal-title":"Cancers (Basel)"},{"key":"65724_CR20","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S1470-2045(14)70025-7","volume":"15","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya, A. et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a\/b gastric cancer (SAMIT): A phase 3 factorial randomised controlled trial. Lancet Oncol. 15, 886\u2013893 (2014).","journal-title":"Lancet Oncol."},{"key":"65724_CR21","doi-asserted-by":"publisher","first-page":"861777","DOI":"10.3389\/fmed.2022.861777","volume":"9","author":"L Su","year":"2022","unstructured":"Su, L. et al. POF (paclitaxel\/oxaliplatin\/5-fluorouracil\/leucovorin) vs. SOX\/CAPOX\/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Front Med. (Lausanne) 9, 861777 (2022).","journal-title":"Front Med. (Lausanne)"},{"key":"65724_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara, K. et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): An open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 277\u2013287 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"65724_CR23","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1111\/cas.13813","volume":"109","author":"MM He","year":"2018","unstructured":"He, M. M. et al. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci. 109, 3575\u20133582 (2018).","journal-title":"Cancer Sci."},{"key":"65724_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cam4.4966","volume":"12","author":"Y Cui","year":"2023","unstructured":"Cui, Y. et al. Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren\u2019s diffuse-type gastric cancer after D2 resection (NORDICA study). Cancer Med. 12, 1114\u20131121 (2023).","journal-title":"Cancer Med."},{"key":"65724_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-020-07772-7","volume":"21","author":"X Cheng","year":"2021","unstructured":"Cheng, X. et al. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: A phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC Cancer 21, 56 (2021).","journal-title":"BMC Cancer"},{"key":"65724_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10120-018-0895-x","volume":"22","author":"X Cheng","year":"2019","unstructured":"Cheng, X. et al. The role of oxaliplatin in the adjuvant setting of different Lauren\u2019s type of gastric adenocarcinoma after D2 gastrectomy: A real-world study. Gastric Cancer 22, 587\u2013597 (2019).","journal-title":"Gastric Cancer"},{"key":"65724_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/cas.12419","volume":"105","author":"Y Sasaki","year":"2014","unstructured":"Sasaki, Y. et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 105, 812\u2013817 (2014).","journal-title":"Cancer Sci."},{"key":"65724_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.21037\/jgo-22-279","volume":"13","author":"J Ma","year":"2022","unstructured":"Ma, J. et al. Analysis of the efficacy and safety of paclitaxel (albumin-bound) combined with S-1 and oxaliplatin combined with S-1 in the first-line treatment of advanced gastric cancer: A cohort study. J. Gastrointest. Oncol. 13, 630\u2013636 (2022).","journal-title":"J. Gastrointest. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65724-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65724-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65724-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:04:23Z","timestamp":1719896663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65724-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65724-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15150"}}